Zentalis Pharmaceuticals, Inc. Income (Loss) from Equity Method Investments
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2024-12-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2024-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2024-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2024-03-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2025 was $0.00.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2024 was $0.00.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2023 was -$16.01M.
- Zentalis Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2022 was -$16.28M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | -$13.70M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | -$13.70M derived: sum of 3 quarters · filed 2026-03-26 | -$16.01M 10-K · filed 2026-03-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | -$13.70M derived: sum of 2 quarters · filed 2024-11-12 | -$16.01M 10-Q · filed 2024-11-12 | -$22.84M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | -$13.70M 10-Q · filed 2024-08-09 | -$16.01M 10-Q · filed 2024-08-09 | -$22.84M derived: sum of 3 quarters · filed 2025-03-26 | -$25.21M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | -$2.31M 10-Q · filed 2024-05-07 | -$9.13M derived: sum of 2 quarters · filed 2025-03-26 | -$11.50M derived: sum of 3 quarters · filed 2025-03-26 | -$16.84M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | -$6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$9.19M derived: sum of 2 quarters · filed 2025-03-26 | -$14.53M derived: sum of 3 quarters · filed 2025-03-26 | -$16.28M 10-K · filed 2025-03-26 |
| 2022-09-30 | -$2.37M 10-Q · filed 2023-11-06 | -$7.71M derived: sum of 2 quarters · filed 2023-11-06 | -$9.46M 10-Q · filed 2023-11-06 | -$11.29M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$5.34M 10-Q · filed 2023-08-09 | -$7.09M 10-Q · filed 2023-08-09 | -$8.92M derived: sum of 3 quarters · filed 2023-08-09 | -$8.92M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.75M 10-Q · filed 2023-05-10 | -$3.58M derived: sum of 2 quarters · filed 2023-05-10 | -$3.58M derived: sum of 3 quarters · filed 2023-05-10 | -$3.58M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$1.83M 10-K · filed 2022-02-24 | -$1.83M derived: sum of 2 quarters · filed 2022-11-09 | -$1.83M derived: sum of 3 quarters · filed 2022-11-09 | -$1.83M 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |